Understanding Canagliflozin’s Role in Blood Pressure Management

Canagliflozin, an oral medication belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, was initially approved for improving glycemic control in adults with type 2 diabetes. Over time, evidence has expanded far beyond glucose lowering, revealing substantial cardiovascular and renal benefits. One of the most clinically relevant effects is a consistent reduction in blood pressure (BP). For patients with diabetes—who frequently also have hypertension—this dual action on glucose and BP offers a powerful tool for reducing long-term risks of heart attack, stroke, and kidney disease. This article reviews how canagliflozin lowers BP, the supporting clinical evidence, and what patients and clinicians should consider when using it for blood pressure management.

What Is Canagliflozin? Mechanism and Primary Effects

Canagliflozin works by selectively inhibiting SGLT2 proteins located in the proximal tubule of the kidney nephron. These transporters are responsible for reabsorbing about 90% of the glucose filtered by the kidneys. By blocking SGLT2, canagliflozin causes glucose to remain in the urine and be excreted, thereby reducing blood glucose levels. This mechanism also produces an osmotic diuresis because the excreted glucose draws water along with it. Furthermore, canagliflozin promotes natriuresis—sodium excretion—which directly affects extracellular fluid volume. The combination of fluid and sodium loss reduces plasma volume, lowers preload, and decreases blood pressure. Additionally, the medication induces a mild weight loss (typically 2–3 kg) and modest reductions in uric acid levels, both of which contribute secondarily to BP improvement. Importantly, these effects occur independently of glycemic control, meaning canagliflozin lowers BP even in patients without diabetes, as demonstrated in heart failure and chronic kidney disease trials.

Why Blood Pressure Matters in Type 2 Diabetes

Hypertension is extremely common among individuals with type 2 diabetes, affecting up to two-thirds of this population. The coexistence of diabetes and hypertension markedly increases the risk of cardiovascular events, progressive kidney disease, and mortality. The pathophysiology involves insulin resistance, activation of the renin-angiotensin-aldosterone system (RAAS), increased sodium retention, and arterial stiffness. Managing blood pressure effectively is therefore a central goal in diabetes care. The American Diabetes Association (ADA) recommends a target BP of <130/80 mmHg for most adults with diabetes. Traditional antihypertensives such as ACE inhibitors, ARBs, thiazide diuretics, and calcium channel blockers are first-line, but many patients require multiple agents. Canagliflozin offers a unique adjunctive mechanism that not only lowers glucose but also produces a meaningful BP reduction, often allowing for dose reductions or discontinuation of other BP drugs.

Epidemiology and Clinical Impact

Data from the National Health and Nutrition Examination Survey (NHANES) indicate that only about half of adults with diabetes achieve BP targets. Each 10 mmHg reduction in systolic BP is associated with a 20–30% decrease in major cardiovascular events. The BP-lowering effect of canagliflozin, although modest on average (3–5 mmHg systolic), is additive to that of standard antihypertensive therapy and is sustained over long-term use. Furthermore, because the effect is largely driven by volume contraction, it may be especially beneficial in patients with salt-sensitive hypertension or resistant hypertension.

How Canagliflozin Lowers Blood Pressure: Multiple Mechanisms

The BP reduction observed with canagliflozin is not attributable to a single mechanism but rather a combination of hemodynamic, metabolic, and vascular effects.

1. Diuresis and Natriuresis

The most direct effect is the increase in urine output (approximately 200–300 mL per day) and sodium excretion. This leads to a contraction of plasma volume by 5–10%, which lowers cardiac preload and systemic blood pressure. The diuretic effect is more pronounced during the first few weeks of therapy but persists to a lesser degree long-term.

2. Improved Arterial Stiffness

Canagliflozin has been shown to reduce arterial stiffness, measured by pulse wave velocity, independent of BP. This may result from reductions in oxidative stress, inflammation, and advanced glycation end products. Improved vascular compliance contributes both to lower systolic BP and narrower pulse pressure.

3. Weight Loss and Adiposity Reduction

Caloric loss through glucosuria typically produces a weight reduction of 2–3 kg over 6–12 months, primarily from fat mass. Loss of visceral adipose tissue reduces sympathetic nervous system activity and improves insulin sensitivity, both of which favor lower BP.

4. Inhibition of the RAAS and Sympathetic Outflow

Emerging evidence suggests SGLT2 inhibitors may downregulate the RAAS by reducing sodium delivery to the macula densa, thereby decreasing renin release. Additionally, some studies indicate a reduction in sympathetic nerve activity, which lowers peripheral vascular resistance.

5. Reduction in Uric Acid Levels

Canagliflozin increases uric acid excretion, lowering serum urate by 10–20%. Elevated uric acid is an independent risk factor for hypertension, and its reduction may contribute to BP improvement, particularly in patients with hyperuricemia.

Clinical Trial Evidence Supporting the BP Effect

Several large randomized controlled trials have quantified the BP-lowering effects of canagliflozin in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors.

The CANVAS Program

The Canagliflozin Cardiovascular Assessment Study (CANVAS) and CANVAS-R enrolled over 14,000 patients with type 2 diabetes at high cardiovascular risk. At baseline, the mean BP was approximately 136/78 mmHg. After a mean follow-up of 188 weeks, patients randomized to canagliflozin (100 or 300 mg) demonstrated a placebo-adjusted reduction in systolic BP of 3.9 mmHg (95% CI –4.7 to –3.2) and diastolic BP of 1.4 mmHg (95% CI –1.8 to –0.9). The effect was consistent across subgroups, including those on multiple antihypertensives. Importantly, the BP reduction was maintained over the entire study period with no evidence of tolerance.

The CREDENCE Trial

The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial evaluated canagliflozin in patients with type 2 diabetes and chronic kidney disease (eGFR 30 to <90 mL/min/1.73 m² and albuminuria). Mean baseline BP was 140/78 mmHg. Over a median follow-up of 2.6 years, canagliflozin reduced systolic BP by 3.5 mmHg compared with placebo, with a similar effect on diastolic BP. The BP reduction was accompanied by a significant 30% reduction in the primary composite outcome of ESRD, doubling of serum creatinine, or renal or cardiovascular death.

Additional Studies and Meta-Analyses

A 2020 meta-analysis pooling 20 randomized trials with over 18,000 participants found that canagliflozin reduced 24-hour ambulatory systolic BP by 3.0 mmHg and office systolic BP by 3.6 mmHg compared with placebo. The effect on 24-hour ambulatory BP was greater during nighttime hours (4.5 mmHg), a pattern associated with improved cardiovascular outcomes. Another meta-analysis specifically in patients with hypertension showed a mean systolic reduction of 4.5 mmHg for canagliflozin 300 mg. These data confirm a robust and clinically meaningful BP-lowering effect.

Cardiovascular and Renal Benefits Beyond BP Reduction

While the BP effect is important, it is only one component of canagliflozin’s cardiovascular protection. In CANVAS, canagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14%. In CREDENCE, it reduced the risk of end-stage kidney disease by 32%. The medication also reduces hospitalizations for heart failure by about 30–35%, an effect that occurs early and independently of baseline BP. These outcomes suggest that canagliflozin confers benefits beyond what would be expected from BP lowering alone, likely through direct effects on cardiac energetics, mitochondrial function, and inflammation.

Potential Risks and Side Effects to Monitor

As with any medication, the BP-lowering effect of canagliflozin must be weighed against potential adverse effects. The diuretic effect can cause volume depletion, leading to symptomatic hypotension (especially in the elderly), orthostatic hypotension, dizziness, and syncope. The risk is higher in patients with baseline low blood pressure, those on loop diuretics, or those with impaired renal function.

Dehydration and Electrolyte Imbalance

Canagliflozin increases the risk of dehydration and hypernatremia. Serum sodium levels should be monitored, particularly when initiating therapy or increasing the dose. Hypomagnesemia has also been observed in some patients.

Genital and Urinary Tract Infections

Because canagliflozin increases glucose in the urine, it raises the risk of genital mycotic infections (e.g., balanitis, vulvovaginitis) and, less commonly, urinary tract infections. Patients should be counseled on hygiene and prompt reporting of symptoms.

Euglycemic Diabetic Ketoacidosis (DKA)

Though rare, SGLT2 inhibitors including canagliflozin have been associated with euglycemic DKA (blood glucose <200 mg/dL but elevated ketones). Patients should be warned to discontinue the medication if they become seriously ill, undergo surgery, or experience symptoms of acidosis (nausea, vomiting, abdominal pain, dyspnea).

Amputation Risk

The CANVAS trial showed an increased risk of lower-limb amputation (primarily toe or forefoot) with canagliflozin (hazard ratio 1.97). The mechanism remains unclear, but caution is advised in patients with prior amputation, peripheral vascular disease, neuropathy, or active foot ulcers. Patient education on foot care is essential.

Renal Function Monitoring

Canagliflozin causes an initial acute drop in eGFR (typically 3–5 mL/min/1.73 m²) due to hemodynamic effects. This is usually reversible and not associated with long-term harm. However, eGFR should be checked before and after initiation. The drug is not recommended for patients with eGFR <30 mL/min/1.73 m² when used for glycemic control, though it may be continued in those with eGFR ≥30 for cardiovascular or renal indications.

Who Should Consider Canagliflozin for Blood Pressure Control?

Given the evidence, canagliflozin is an attractive option for patients with type 2 diabetes and inadequately controlled hypertension, particularly those with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. It is also approved in many countries for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status and for chronic kidney disease. In these populations, the BP-lowering effect is a welcome addition, but the primary indication is driven by organ protection.

For patients with type 2 diabetes and hypertension, canagliflozin can be added to existing antihypertensive therapy. Because it may reduce the need for other BP medications, close monitoring of BP in the first 2–4 weeks is recommended. The medication is generally not suitable for patients with a history of recurrent genital infections, active foot ulcers, or those at high risk of amputation. It should be used with caution in elderly patients prone to volume depletion.

Comparing Canagliflozin to Other SGLT2 Inhibitors

The class includes empagliflozin, dapagliflozin, and ertugliflozin. All four agents produce similar BP reductions (2–5 mmHg systolic), and all have demonstrated cardiovascular and renal benefits. However, there are subtle differences. Empagliflozin showed a significant reduction in cardiovascular death in the EMPA-REG OUTCOME trial, while canagliflozin had a broader reduction in MACE (composite of cardiovascular death, MI, stroke). Dapagliflozin reduced heart failure hospitalizations and CV death in HFrEF (DAPA-HF). The magnitude of BP effect is comparable, though canagliflozin has the strongest evidence for reducing progression of kidney disease in type 2 diabetes from the CREDENCE trial. Choice among SGLT2 inhibitors may depend on individual patient factors, specific outcomes proven in trials, cost, and tolerability.

Integrating Canagliflozin into a Comprehensive Hypertension Management Plan

Canagliflozin should not replace standard antihypertensive therapy but rather complement it. For patients already on maximally tolerated doses of an ACEi or ARB, the addition of canagliflozin can provide additional BP reduction without the metabolic side effects of thiazides (hypokalemia, hyperglycemia) or beta-blockers (bradycardia, fatigue). In patients with resistant hypertension, canagliflozin may be particularly useful because it addresses fluid overload, a common underlying factor. The combination with loop diuretics should be managed carefully to avoid excessive volume depletion.

Nonpharmacological measures remain the cornerstone of BP management: salt restriction ( <2.3 g/day), a diet rich in fruits and vegetables, regular physical activity, weight reduction, and moderation of alcohol intake. Canagliflozin’s weight-lowering effect synergizes with lifestyle changes. Patients should be educated about the expected diuretic effect and advised to stay well-hydrated, especially in hot weather or during illness.

Practical Considerations for Prescribers

Before starting canagliflozin, evaluate renal function, serum electrolytes, blood pressure, and history of relevant conditions. The typical starting dose for glycemic control is 100 mg once daily, which also provides a moderate BP effect. The dose can be increased to 300 mg once daily if needed, with an additional 1–2 mmHg BP reduction. For patients with eGFR 30–45 mL/min/1.73 m², the recommended starting dose is 100 mg (for renal protection), and the 300 mg dose is not recommended. Monitor BP and renal function 2–4 weeks after initiation and periodically thereafter. Caution patients about the risk of orthostatic hypotension, especially when rising from a seated or lying position. Advise them to report symptoms of urinary tract infection, genital irritation, or ketosis.

Conclusion

Canagliflozin provides a clinically meaningful reduction in BP in patients with type 2 diabetes, typically in the range of 3–5 mmHg systolic. This effect is mediated through diuresis, natriuresis, weight loss, improved arterial compliance, and modulation of neurohormonal pathways. In large outcome trials, the BP reduction contributed to—but did not fully account for—substantial reductions in cardiovascular and renal events. When appropriately prescribed and monitored, canagliflozin is a valuable addition to the armamentarium for managing hypertension in diabetic patients, especially those with high cardiovascular risk. As with all medications, the benefits must be weighed against the risks, particularly volume depletion, infections, and the rare but serious risk of amputations. Working in concert with lifestyle measures and standard antihypertensives, canagliflozin can help more patients achieve optimal blood pressure control and better long-term outcomes.

External References: